Introduction
Nephropathy due to type 2 diabetes mellitus is the leading cause of end-stage renal disease. A key factor in the progression of diabetic and non-diabetic renal disease is the renin-angiotensin system (RAS). In humans, or rodent models, angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin II (AngII) type 1 receptor blockers (ARBs) are effective in the prevention and control of renal damage. In experimental settings inhibitors of RAS even reversed the established non-diabetic renal injury [1] [2] [3] , while pancreatic transplantation in humans reversed diabetic nephropathy (DN) [4] .
Obese Zucker rats (OZRs, a model of type 2 diabetes mellitus), develop hyperphagia, obesity, hyperglycemia, hyperinsulinemia, hyperlipidemia, hyperaggregation of platelets, moderate hypertension, and (at approximately 40 weeks of age) renal damage [5] . The effects of ACEIs, ARB and their combination in preventing renal injury in OZRs have already been described [6] , but not evaluated in established DN. We show that 8-week treatment with the ACEI perindopril and the ARB candesartan, initiated in established DN, ameliorates and even reverses functional and several aspects of glomerular kidney damage.
Materials and Methods

Animals
The research protocol was approved by the Ethics Committee for Animals (Bratislava, Slovakia). Forty 1-month-old male OZRs (Iffa Credo, Lyon, France) were subjected to unilateral nephrectomy under intraperitoneal ketamin/xylazin anesthesia [7] . Animals were housed under standard conditions with free access to water. After uninephrectomy, rats were switched from standard chow to a high-protein diet (50%, Altromin, Lage, Germany). Four months later they were randomized into 4 groups (10 animals/group) with comparable proteinuria ( fig. 1 ). Control rats were sacrificed before any treatment was initiated. By gavage, placebo rats received a 1% water solution of hydroxyethyl cellulose (HEC) in a volume of 5 ml/kg. Perindopril (Servier, Paris, France) was administered at a dose of 1 mg/kg/day, and candesartan cilexetil (Astra Zeneca, Wedel, Germany) at a dose of 10 mg/kg/day, dissolved in 1% HEC, 7 days/week for 8 weeks.
Rats were weighed weekly. Before sacrifice, systolic blood pressure (SBP) was measured by tail phethysmography. Twentyfour-hour urine was collected in metabolic cages before randomization and sacrifice. Blood was sampled under anesthesia from the abdominal aorta.
Biochemical Analyses
Routine blood and urine biochemistry (Vitros 250 Analyzer; J&J, Rochester, Minn., USA) and blood count (Sysmex K-21 Analyzer; Kobe, Japan) were analyzed. In plasma, the immunoreactive insulin concentration (Linco Research, St. Charles, Mo., USA) and advanced oxidation protein products (AOPPs) [8] , and in erythrocytes glutathione peroxidase (GPX) activity (Randox Laboratories, Crumlin, UK) were determined.
Renal Histology
After retrograde perfusion fixation with glutaraldehyde via the abdominal aorta, kidneys were weighed and dissected into 1-mm-wide slices in a plane perpendicular to the interpolar axis [7] . Ten pieces/kidney were embedded in Epon-Araldite. Semithin (1-m) slices were stained with methylene blue and basic fuchsin. Four-micrometer sections embedded in paraffin were stained with hematoxylin/eosin (HE) and periodic acid-Schiff (PAS). All morphological evaluations were performed in a blinded manner.
Morphological Investigations
Semiquantitative Mesangiolysis (a hallmark of early glomerular damage in DN) was determined utilizing a 0-4 scoring system (0 = normal to 4 = severe damage) in 100 glomeruli/animal [7] .
The degree of mesangial matrix expansion and sclerosis within the glomerular tuft (an index of progression) was determined on PAS-stained sections using a semiquantitative scoring system from 0 to 4 (0 = normal glomerulus, 4 = severe damage) in 100 glomeruli/animal [7, 9] .
Tubulointerstitial and vascular damage indices were assessed on PAS-stained paraffin sections using the previously described scoring system [7, 9] .
Glomerular Geometry
The volume density of glomeruli and the area density of glomerular tufts were measured by point counting on HE sections [7, 9] . The total number of glomeruli was derived from the total volume of the renal cortex and the number of glomeruli per cortex volume. The mean glomerular tuft volume was determined.
Semithin sections were qualitatively inspected for glomerular cellular changes (podocyte hypertrophy and degeneration, and mesangial or endothelial cell hyperplasia). Five sections/animal (at least 30 glomeruli) were analyzed quantitatively for glomerular cell number and volume determination [9] . ( table 1 ) During treatment, the body weight of the placebo rats remained stable, while it tended to decrease in the treated groups. Compared to placebo, perindopril-and candesartan-treated rats had lower SBP by 16% (-23 mm Hg; p ! 0.001) and 10% (-14 mm Hg; p ! 0.05), respectively. Kidney weight was higher in placebo rats (+55%, p ! 0.01 vs. controls). Both treatments effectively halted hypertrophy, but after correction for body weight it remained significant only in the candesartan group (vs. placebo, p ! 0.05). ( table 1 ) An insignificant rise in mean plasma creatinine (21%), and a decreased creatinine clearance (-12%; n.s.) were observed in placebo rats (vs. controls). Both treated groups had an insignificantly higher plasma creatinine concentration (+16% vs. placebo), and lower creatinine clearance (perindopril -33%; candesartan -14%; n.s.).
Results
Body Weight, Kidney Weight and SBP
Renal Function
At treatment initiation, groups had comparable diuresis and proteinuria ( fig. 2, 3 ). After treatment, diuresis increased. In the placebo group proteinuria increased (+21%; n.s.), perindopril and candesartan lowered proteinuria to 32 (p ! 0.01) and 37% (p ! 0.001) of pretreatment values, respectively.
Kidney Morphology ( fig. 4, 5 ; table 2 ) DN in placebo rats markedly progressed during the treatment period: mesangiolysis (+100%); glomerulosclerosis (+33%); tubulointerstitial fibrosis (+56%), and vascular damage scores (+61%) increased (all p ! 0.001). Candesartan stopped the progression of mesangiolysis, while perindopril reversed it (-32%). Both treatments halted the progression of glomerulosclerosis. Mild tubulointerstitial or vascular damage remained unaffected.
Placebo rats developed glomerular hypertrophy; perindopril slightly ameliorated it (-11% vs. placebo; n.s.). The total number of glomerular cells did not differ significantly between placebo and control rats. In both treatment groups endothelial cell and podocyte numbers were significantly higher than in the placebo group. In parallel, with a trend towards lower endothelial cell number, glomerular capillary length density (as a three-dimensional parameter of glomerular capillarization) was significantly lower in the placebo group vs. the controls. Both treatments had no significant effect on glomerular capillarization. ( table 1 ) All rats were hyperglycemic. Placebo rats had higher insulinemia than the controls, or candesartan-administered animals. All groups showed dyslipidemia, which was not significantly reduced by the treatments. Placebo rats had significantly higher leukocyte count (vs. controls), which was insignificantly reduced by both treatments.
Blood Chemistry
Oxidative Status ( table 1 ) Plasma AOPPs did not differ significantly between the control and placebo groups. Candesartan reduced AOPP levels (-38% vs. placebo; p ! 0.01). GPX activity was significantly lower in the placebo rats (vs. the controls), and both treatments only partially restored it.
Discussion
To date, no data are available on the secondary prevention of renal injury in the OZRs by blockade of the RAS. The major finding of this study shows that the RAS blockade in established DN in OZRs, either with perindopril or candesartan, not only halts the progression of several markers of renal injury, but even induces a partial regression of glomerular damage. Both treatments retarded the progression of glomerulosclerosis and preserved glomerular cells (podocytes, endothelial cells, glomerular capillary supply). Candesartan halted and perindopril induced a limited regression of mesangiolysis (in contrast to other studies) [6] . Tubulointerstitial and vascular sclerosis scores were not significantly affected. Both treatments suppressed proteinuria. The missing effect on the extraglomerular structures may reflect the persisting risk factors of renal damage, e.g. hyperglycemia, hypertension, dyslipidemia, obesity, and high protein intake. Moreover, in the OZRs the systemic RAS is downregulated, limiting the effect of ACE inhibition/blockade [10] . A major mechanism of renoprotection under RAS blockade is the antihypertensive effect, as in our study. However, the decline in blood pressure seems to be too mild to explain the marked improvement in renal injury, thus other mechanisms have to be considered.
Oxidative Stress
AngII promotes generation of reactive oxygen species (ROS) which worsen insulin resistance, diabetes, and its complications [11] . AOPPs reflect, and trigger, an oxidative burst of phagocytes [8] . In our study, candesartan lowered AOPP levels, similar to peritoneal dialysis patients [12] . In line with the increased AOPPs, the placebo rats had a higher leukocyte count which, even within the normal range, is associated with macro-and microvascular complications in diabetics [13] . While perindopril increased the activities of antioxidant enzymes in hypertensive patients [14] , decreased GPX activity in our placebo rats was only partially restored under both treatments. Thus, other antioxidative mechanisms could have been involved.
Carbohydrate/Lipid Metabolism ARB administration decreases peripheral insulin resistance in type 2 diabetics and animal models [15] . We observed the insulin-sensitizing effects of candesartan, 100 μm 100 μm 100 μm 100 μm similar to a study in OZRs administered irbesartan [16] . Neither treatment influenced dyslipidemia, despite the reduction in proteinuria. In other studies candesartan either lowered or induced mild changes in plasma lipids [17, 18] . Although perindopril did not significantly affect metabolic parameters, in hypertensive type 2 diabetics it improved some metabolic parameters compared with candesartan [18] .
Fat Tissue
Obesity is a risk factor for progression of renal disease [19] . Adipocytes produce all components of the RAS [20] . RAS blockade in rodents lowered body weight gain, fat mass, adipocyte size and AT 1 receptor number [21] . Thus, the decline in body weight in both treatment groups could be another protective mechanism of RAS blockade. However, in clinical studies, lowering of body weight under RAS blockade has not been reported.
Renal Mechanisms
In line with previous reports [3, 22, 23] , preservation of podocytes, glomerular endothelial cells, and reduced mesangial sclerosis were important renoprotective effects of RAS blockade also in established DN in OZRs. As vascular endothelial growth factor (VEGF) is considered a key downstream mechanism, the preservation of endothelial cells and podocytes could have been mediated via VEGF. Perindopril resulted in higher capillary density and VEGF synthesis in the myocardium of OZRs [24] , and in the ischemic hindlimb of diabetic mice [25] .
The lowered glomerular filtration rate in the treated groups is most probably functional, partly via decreased systemic blood pressure, as is well known after ACEI administration [26] .
Since single ACEI and ARB compounds differ in their pharmacological properties, we cannot conclude whether our data represent a class effect or merely that of the drugs employed. It is unclear whether RAS blockade could reverse DN also in humans.
In conclusion, the late intervention with perindopril and candesartan in established DN in uninephrectomized OZRs halted the progression and even induced a partial regression in glomerular injury, preserving glomerular cells and capillaries. The blood pressure-lowering actions of RAS blockade as well as additional effects (reduction of oxidative stress, improved carbohydrate metabolism) are to be considered, in particular for candesartan. krankheiten Würzburg e.V., Germany. The technical assistance of Monika Klewer and Miriam Ramming is gratefully acknowledged. 
